Funding for this research was provided by:
Received: 15 January 2021
Accepted: 18 February 2021
First Online: 16 March 2021
Ethics approval and consent to participate
: The clinical protocol was approved by an independent ethics committee or institutional review board at each participating center (listed in Additional file InternalRef removed: Appendix S1). All patients provided written informed consent before study entry.
: Not applicable.
: VC reports research grants, personal fees, and non-financial support from Boehringer Ingelheim; personal fees from AstraZeneca, Bayer, Merck Sharp & Dohme, Celgene, FibroGen, Galapagos, Galecto, Novartis, Sanofi, and Shionogi; and personal fees and non-financial support from Actelion, and Roche/Promedior. LR reports personal fees from Asahi Kasei, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL Behring, FibroGen, ImmuneWorks, Nitto, Pliant Therapeutics, Promedior, Respivant, Roche, and Toray. IR reports personal fees from Boehringer Ingelheim and Genentech/Roche and grants from Genentech/Roche. MO reports personal fees from Boehringer Ingelheim and Bristol-Myers Squibb. JWS has nothing to disclose. ST reports personal fees from Boehringer Ingelheim and Roche and grants from Roche. MW reports grants paid to her institution from Boehringer Ingelheim and Hoffman-La Roche and fees paid to her institution from Boehringer Ingelheim, Hoffman-La Roche, Galapagos, Respivant, Novartis, and Savara. MS is an employee of mainanalytics GmbH, which was contracted by Boehringer Ingelheim to conduct analyses presented in this manuscript. CC, SSt, and RSH are employees of Boehringer Ingelheim. MK reports personal fees from AstraZeneca, Boehringer Ingelheim, Covance, Galapagos, Gilead, GlaxoSmithKline, Indalo, Prometic, Roche, and Third Pole, Inc and grants from Boehringer Ingelheim, Gilead, GlaxoSmithKline, Prometic, and Roche.